Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Lukas Biomedical Inc. (6814.TWO), each with what it measures. Figures are trailing twelve months or the most recent reported period.
Valuation
Metric
Value
P/E ratioShare price divided by earnings per share.
0.00
P/B ratioShare price divided by book value per share.
4.05
P/S ratioMarket value divided by annual revenue.
4.56
Profitability
Metric
Value
Gross marginRevenue left after the direct cost of goods sold.
59.88%
Operating marginRevenue left after operating costs.
-60.04%
Net marginRevenue left after every cost, including tax and interest.
-54.14%
Return on equityProfit as a percentage of shareholders’ equity.
-38.79%
Return on assetsProfit as a percentage of total assets.
-11.76%
Financial health
Metric
Value
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.
0.56
Quick ratioThe same, excluding inventory.
0.23
Debt to equityTotal borrowings against shareholders’ equity.
1.30
Per share and size
Metric
Value
Earnings per shareProfit attributable to each share.
$-2.20
Book value per shareShareholders’ equity divided by shares outstanding.
$4.57
Shares outstandingShares currently issued.
41,874,000
Market capitalisationShare price times shares outstanding.
$774.67M
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.
$0
EmployeesReported headcount.
87
Dividend
Metric
Value
Dividend yieldAnnual dividend as a percentage of the share price.
0.00%
Payout ratioShare of profit paid out as dividends.
0.00%
Lukas Biomedical Inc. (6814.TWO) statistics — frequently asked questions
What is Lukas Biomedical Inc.'s return on equity?
Lukas Biomedical Inc. (6814.TWO) reports a return on equity of -38.79%, meaning it generated that much profit for every dollar of shareholders' equity.
How much debt does Lukas Biomedical Inc. carry?
Lukas Biomedical Inc. (6814.TWO) has a debt-to-equity ratio of 1.30, which compares total borrowings with shareholders' equity.
What is Lukas Biomedical Inc.'s profit margin?
Lukas Biomedical Inc. (6814.TWO) keeps -54.14% of revenue as net profit after every cost, including tax and interest.